뒤로
Anavex Life Sciences Corp (AVXL) 수입
AVXL 주가 차트
AVXL 수입
Anavex Life Sciences Corp
$2.74
-34.6%
$-1.45
종가: Mar 25, 16:00:00 GMT-4
$2.73
-0.36%
$-0.01
애프터마켓: Mar 25, 18:04:19 GMT-4
최신 수익 결과: Q1 '26
보고됨: 2026-02-09
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
AVXL의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Anavex Life Sciences Corp AVXL의 지난 분기 매출 실적은 어땠나요?
Anavex Life Sciences Corp의 매출 추정치는 얼마인가요?
Anavex Life Sciences Corp의 수익 품질 점수는 얼마인가요?
Anavex Life Sciences Corp는 언제 수익을 보고하나요?
Anavex Life Sciences Corp의 예상 수익은 얼마인가요?
Anavex Life Sciences Corp은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$4.19
시가
$3.02
일일 범위
$2.61 - $3.11
52주 범위
$2.73 - $13.99
거래량
14.0M
평균 거래량
1.3M
배당수익률
--
EPS(TTM)
-0.46
시가총액
$252.9M
AVXL란 무엇인가요?
Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. The company is headquartered in New York City, New York and currently employs 34 full-time employees. The company went IPO on 2006-04-13. The firm analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. The company has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.